Genetic Testing for Hereditary Cancers Can Help Reduce the Risk of Cancer
By detecting cancer early, your patient will have access to preventative measures and proactive treatment – leading to an overall better prognosis.
Genetic Diagnosis of Hereditary Cancer
Testing for hereditary cancers can detect specific, heritable, disease-related gene mutations that may increase the risk of certain cancers allowing an in-depth cancer risk assessment for each patient.
The critical goal is to detect cancer early and to give you the opportunity to maximize health outcomes for your patients. Patient-tailored screening programs, preventive measures and proactive treatment are possible for patients of a high-risk group. Early diagnosis can mean a better overall prognosis through a choice of surgical and non-surgical treatment options.
Hereditary Cancer Feature List
Excellent analysis using the most advanced NGS technology
Includes detection of Copy Number Variants (CNVs)
Affordable prices and shortest turnaround times
Highest level of quality/accuracy
CAP and CLIA and ISO certification and accreditation
Breast and Ovarian Cancer
Providing critical information for affected and non-affected individuals
Comprehensive Cancer Panel
CentoCancer® – CENTOGENE's cancer-risk-related panel, for all patients with a positive family history of cancer
Breast and Ovarian Cancer
Breast cancer is one of the most common cancers in the world affecting ~12.5% of women during their lifetime. 5–10% of these patients have a hereditary form.
Mutations in the BRCA1 and BRCA2 genes are the most common hereditary cause. However, other genes such as ATM, BRIP1, CHEK2, PALB2, RAD51, etc. have also been associated with increased risk.
| Gene test | BRCA1/BRCA2 | CentoBreast® |
|---|---|---|
| Gene name | BRCA1, BRCA2 | ABRAXAS1, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CHEK2, DICER1, EPCAM, FANCC, MEN1, MLH1, MRE11, MSH2, MSH6, MUTYH, NBN, PALB2, PMS1, PMS2, PTEN, RAD50, RAD51C, RAD51D, RECQL, SMARCA4, STK11, TP53, XRCC2 |
| Diseases covered | Breast cancer | Breast cancer, ovarian cancer |
| Turnaround time | 15 business days | 15 business days |
| How to order | Order a test | Order a test |
Comprehensive Cancer Panel
CentoCancer® is a specific and sensitive panel with all known highly penetrant cancer genes. Each gene has been carefully selected based on its risk potential in the development of one of the following cancers: breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer.
| Gene test | CentoCancer® |
|---|---|
| Genes name | ABRAXAS1, APC, ATM, AXIN2, BAP1, BARD1, BLM, BMPR1A, BRCA1, BRCA2, BRIP1, CDH1, CDK4, CDKN2A, CHEK2, DICER1, DIS3L2, EPCAM, FANCC, FH, FLCN, GALNT12, HNF1B, HOXB13, KIT, MC1R, MEN1, MET, MITF, MLH1, MLH3, MRE11, MSH2, MSH3, MSH6, MUTYH, NBN, NF1, NTHL1, PALB2, PMS1, PMS2, POLD1, POLE, POT1, PRSS1, PTCH1, PTEN, RAD50, RAD51C, RAD51D, RECQL, RET, RNF43, SDHA, SDHAF2, SDHB, SDHC, SDHD, SMAD4, SMARCA4, STK11, TGFBR2, TP53, TSC1, TSC2, VHL, WT1, XRCC2, XRCC3 |
| Diseases covered | Breast, ovarian, colorectal, gastric, bowel, endometrial, pancreatic, melanoma, renal and prostate cancer |
| Turnaround time | 15 business days |
| How to order | Order a test |
Resources
Useful Links
Downloads
Hereditary Cancer Panels – Product Sheet
Genetic testing for an improved prognosis
Scientific Publications
Retrospective Diagnosing of Rare Disease Patients
Despite diagnostic exome/genome sequencing, patients remain without a diagnosis when the relevant gene-disease association is not yet known at the time of analysis. CENTOGENE therefore re-evaluates […]
Related Webinars
NEW CentoXome – Turning Years Into Days
Throughout the CentoTalk, Maximilian Schmid, M.D., and Jorge Pinto Basto, M.D., will provide a detailed overview of CENTOGENE’s new and enhanced Whole Exome Sequencing (WES) solution.
Webinar de CentoGenome - ‘Una mirada al poder de la Secuenciación del Genoma Completo’
Acompáñenos en nuestro CentoWebinar ‘Una mirada al poder de la secuenciación del genoma completo.’ A lo largo del webinar, nuestro presentador el Dra. Aida M. Bertoli-Avella, MD le proporcionará una […]
CentoGenome Webinar - ‘A Look Into the Power of Whole Genome Sequencing’
Throughout the webinar, Prof. Peter Bauer will provide you with an overview of Whole Genome Sequencing (WGS) and share insights from our latest study – unlocking the clinical utility of WGS.
Get in Touch With Our Customer Support
Our consultation service is available in several languages.
+49 (0) 381 80 113 - 416
Mon. – Fri. 7 a.m. – 6:30 p.m. CET
Sat. 8 a.m. – 12 p.m. CET